ABT vs ACT · P/E 25, rev $44.33B vs P/E 9.3, rev $1.20B
Abbott Laboratories (ABT) versus Enact Holdings Inc (ACT) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Enact Holdings Inc (ACT) is a insurance - specialty company listed on NASDAQ.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported ACT revenue for 2024-12-31 was $1.20B. Revenue was up 4.2% from 2023-12-31 to 2024-12-31. ACT currently screens at market cap $5.99B and trailing P/E 9.3.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. ACT currently screens at market cap $5.99B and trailing P/E 9.3.
Not investment advice. Open the ABT and ACT stock pages for the full models.
Not investment advice.